Citi analyst Joanne Wuensch reiterated a Buy rating on Glaukos today and set a price target of $125.00. According to TipRanks, Wuensch is a 4-star analyst with an average return of 3.8% and a 55.83% ...

Welcome to the Barclays Miami Healthcare Conference. I'm Jenna Davidner. I'm one of the analysts here on the specialty pharmaceuticals team and very pleased to have Tarsus Pharmaceuticals on the stage ...

Irvine-based Tarsus Pharmaceuticals posted blockbuster Q4 and full year revenues driven by surging demand for its eyedrop ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, ...

Consultant ophthalmologist, Sharmina Khan, outlined current and emerging therapies for dry eye disease during her 100% ...

In better news: They're totally treatable and actually pretty common (especially for makeup wearers).

Research shows that patients with Demodex blepharitis have significantly higher prevalence of ocular bacterial or fungal ...

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD ...

Patients with Demodex blepharitis show significantly higher rates of microbial co-infestation than healthy controls.

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year ...

OMAHA, NE - January 22, 2026 - PRESSADVANTAGE - Modern Vision Solutions has announced the publication of a new article, ...